NASDAQ:BBI Brickell Biotech (BBI) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free BBI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.77▼$0.9352-Week Range N/AVolume31,300 shsAverage Volume206,730 shsMarket Capitalization$6.75 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Brickell Biotech alerts: Email Address Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Brickell Biotech Stock (NASDAQ:BBI)Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.Read More Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW BBI Stock News HeadlinesOctober 19, 2023 | bizjournals.comBrickell hotel sold by royal family member for $55MAugust 27, 2023 | dailymail.co.ukPaul Simon and Edie Brickell's daughter speaks out following parents' arrestMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…April 25, 2023 | bizjournals.comSeattle Biotech NewsApril 10, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Size by 2030March 29, 2023 | travel.usnews.comBrickell City CentreMarch 24, 2023 | bizjournals.comBiotech NewsMarch 18, 2023 | techcrunch.com5 strategies for biotech startups to outlast a market downturnMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 14, 2023 | marketwatch.comNuclear Receptor ROR-Gamma Market Application, Product, Sales and Forecast 2023-2028February 27, 2023 | finance.yahoo.comWhat Sunzen Biotech Berhad's (KLSE:SUNZEN) P/E Is Not Telling YouFebruary 27, 2023 | techcrunch.comBiotech proved a surprisingly bright spot in 2022’s startup correctionFebruary 21, 2023 | msn.comPaul Simon Was 50 When He Married a 26-Year-Old Edie BrickellFebruary 19, 2023 | cnbc.comThis biotech hedge fund has elite clients like Yale’s endowment, Tisch. Here are its top betsFebruary 10, 2023 | benzinga.comBest Biotech Penny StocksJanuary 13, 2023 | markets.businessinsider.comVERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery SystemJanuary 9, 2023 | cbsnews.comUSDA approves vaccine for honeybees, biotech company saysJanuary 4, 2023 | marketwatch.comBioreactors and Fermenters Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2028December 28, 2022 | forbes.comBrickell BiotechDecember 18, 2022 | marketwatch.comNuclear Receptor ROR-Gamma Market : Industry Analysis 2023 To 2028 based on Sales, Revenue, Size and ShareDecember 5, 2022 | nz.finance.yahoo.comAtopic Dermatitis Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightSeptember 13, 2022 | finance.yahoo.comFresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02September 7, 2022 | finance.yahoo.comBrickell Biotech Announces Corporate Rebranding to Fresh Tracks TherapeuticsAugust 11, 2022 | seekingalpha.comBrickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call TranscriptAugust 2, 2022 | benzinga.comBrickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022July 20, 2022 | finance.yahoo.comBrickell Biotech Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 6, 2022 | finance.yahoo.comBrickell Biotech to Participate at William Blair Biotech Focus Conference 2022See More Headlines Receive BBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brickell Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2022Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BBI CUSIPN/A CIK819050 Webwww.brickellbio.com Phone(720) 505-4755Fax858-646-1150Employees16Year Founded2009Profitability EPS (Most Recent Fiscal Year)($13.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,470,000.00 Net Margins-643.48% Pretax Margin-643.48% Return on Equity-156.10% Return on Assets-128.23% Debt Debt-to-Equity RatioN/A Current Ratio6.36 Quick Ratio6.36 Sales & Book Value Annual Sales$4.64 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$9.75 per share Price / BookN/AMiscellaneous Outstanding Shares2,874,000Free Float2,744,000Market Cap$6.75 million OptionableNot Optionable Beta0.02 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Reginald L. Hardy M.B.A. (Age 64)R.Ph., Co-Founder & Chairman Comp: $76.83kAttorney Robert Busard Brown (Age 60)CEO & Director Comp: $816.73kMr. Andrew D. Sklawer (Age 38)Co-Founder, Pres, COO & Sec. Comp: $559.58kMr. Deepak Chadha M.B.A. (Age 52)M.S., MBA, MS, RAC, Chief R&D Officer Comp: $543.59kMr. Albert Nicholas Marchio II (Age 70)CFO and Principal Accounting & Financial Officer Mr. David R. Mcavoy J.D. (Age 59)Gen. Counsel & Chief Compliance Officer Mr. Gary S. Walker (Age 62)Chief Marketing Officer Aron Aizenstat M.B.A.P.M.P., VP of Corp. Devel. & OperationsMs. Sue FattorHead of Human ResourceMs. Nancy SerettaVP & Head of Clinical OperationsMore ExecutivesKey CompetitorsCreative Medical TechnologyNASDAQ:CELZEiger BioPharmaceuticalsNASDAQ:EIGRTitan PharmaceuticalsNASDAQ:TTNPFresh Tracks TherapeuticsNASDAQ:FRTXNanoString TechnologiesNASDAQ:NSTGView All Competitors BBI Stock Analysis - Frequently Asked Questions How were Brickell Biotech's earnings last quarter? Brickell Biotech, Inc. (NASDAQ:BBI) announced its quarterly earnings results on Thursday, August, 11th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($1.48) by $1.47. Brickell Biotech had a negative trailing twelve-month return on equity of 156.10% and a negative net margin of 643.48%. During the same period in the previous year, the firm earned ($7.21) earnings per share. When did Brickell Biotech's stock split? Brickell Biotech shares reverse split before market open on Tuesday, July 5th 2022. The 1-45 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Brickell Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Brickell Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (vbiv), Jaguar Health (JAGX), Miragen Therapeutics (MGEN), Acasti Pharma (ACST), Allena Pharmaceuticals (ALNA), Aileron Therapeutics (ALRN), Amarin (AMRN), Fortress Biotech (FBIO) and iBio (IBIO). This page (NASDAQ:BBI) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brickell Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.